An Experienced Partner for Bringing Advanced Cell and Gene Therapies to Market

Cell and gene therapies, oncolytic viruses and vaccines, and radiolabeled ligands are highly promising treatment modalities, but their newness adds a great deal of complexity to the development path. From devising appropriate immunogenicity assays to maintaining strict chain-of-identity tracking for autologous treatments, these approaches require a clinical development partner with flexible processes and specialized expertise.

At Precision, we understand the logistical and scientific nuances involved in developing these exciting new approaches and we have the track record to prove it.

An Experienced Partner for Bringing Advanced Cell and Gene Therapies to Market

Cell and gene therapies, oncolytic viruses and vaccines, and radiolabeled ligands are highly promising treatment modalities, but their newness adds a great deal of complexity to the development path. From devising appropriate immunogenicity assays to maintaining strict chain-of-identity tracking for autologous treatments, these approaches require a clinical development partner with flexible processes and specialized expertise.

At Precision, we understand the logistical and scientific nuances involved in developing these exciting new approaches and we have the track record to prove it.

50+
POSTERS, PRESENTATIONS AND PANELS
45+
PRECLINICAL THROUGH PHASE III STUDIES COMPLETED
90+
CELL AND GENE THERAPY PROJECTS ACROSS DEVELOPMENT AND COMMERCIALIZATION
Cell Therapy

Our experience developing multiple types of cellular therapies gives us the understanding to develop bespoke solutions for each therapeutic cell type including CAR T cells, stem cells, & tumor-infiltrating lymphocytes.

Gene Therapy

With leadership in immunogenicity, a regulatory team that coordinates therapeutic and companion diagnostic strategy, and a focus on executing end-to-end clinical trials, Precision is well-positioned to guide successful gene therapy development.

Advancing preclinical through pivotal gene and cell therapy studies with logistical and scientific expertise

With 45+ preclinical through phase III studies successfully completed and a dedicated team with even broader first-hand experience, Precision is uniquely equipped to advance development of cell and gene therapies, oncolytic viruses and vaccines, and radiolabeled ligands.

Cell therapy study experience
  • CAR T cells
  • Stem cells
  • Autologous and allogeneic products
  • Tumor-infiltrating lymphocytes
  • TCRs Therapy

 

Gene therapy study experience

Indications:

  • Leber’s congenital amaurosis
  • AADC deficiency
  • Recurrent glioblastoma or gliosarcoma
  • Hemophilia B

Vectors:

  • Multiple AAV serotypes
  • Lentivirus

See all >

Oncolytic virus and vaccine study experience
  • Oncolytic virus
  • Oncolytic adenovirus
  • Cancer Vaccine
  • AAV

 

Radiolabeled study experience
  • Advanced Solid Tumor (ST), Head and Neck, NSCLC
  • Prostate/Solid tumour
  • Metastatic Cancer Expressing NTSR-1

Discover how our cell and gene therapy expertise can advance your clinical development program

Discover how our cell and gene therapy expertise can advance your clinical development program

Services that support the development of cell & gene therapies

Clinical Development Strategy

Tailored strategies consider the scientific, regulatory, and commercial factors that shape each trial, mitigating risk and advancing the development pathway.

Immune Monitoring

Leverage sophisticated immune monitoring approaches, including flow, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

Bioanalytical Testing

Bioanalytical analysis of biologics, cell therapies, gene therapies, and companion diagnostics development from the globally-recognized leaders in immunogenicity testing.

Explore other areas of expertise